WARSAW - Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, today announced preliminary results from a prospective, randomized controlled clinical trial to evaluate the impact of mymobility with Apple Watch, a first-of-its-kind remote care management platform.
The data were presented at the 2020 annual meeting of the American Association of Hip and Knee Surgeons (AAHKS), held November 5-8 in Dallas.
mymobility with Apple Watch enables frequent, virtual connections between patients and healthcare professionals throughout the joint replacement surgery journey with the goal of facilitating remote episode of care management and lowering the overall cost of care. These data show that using the mymobility remote care management platform on Apple Watch and iPhone for primary knee arthroplasty demonstrated similar early outcomes to traditional care models, while requiring significantly fewer physical therapy visits (p
(C) 2020 Electronic News Publishing, source ENP Newswire